In this issue:
Tocilizumab for severe or critical COVID-19
Tocilizumab for COVID-19 patients in ICU
MRI analysis of otilimab for rheumatoid arthritis
IFNα subtypes and IFNω inhibitor JNJ-55920839 phase I trial
Otilimab in patients with hand osteoarthritis
Secukinumab for non-radiographic axial spondyloarthritis
Long-term remission and biologic persistence rates
Giant cell arteritis treated with tocilizumab
Sirukumab for giant cell arteritis
Please login below to download this issue (PDF)